Head-to-head evidence
TGRX-326 vs WX-0593
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: ALK;ROS1 · full Non-Small Cell Lung Cancer pipeline
TGRX-326
Developed by Shenzhen TargetRx
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
WX-0593
Developed by Qilu Pharmaceutical
NCT04632758 · Phase 3 · status unknown
Patients were randomly assigned to WX-0593 or crizotinib, but the study is open-label, meaning patients and doctors both know which drug is being given, which is a weaker design than a blinded trial even though the primary measure, progression-free survival, is a hard clinical outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: March 2027 · NCT05765877 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: TGRX-326's landscape · WX-0593's landscape